Although obinutuzumab has not yet received FDA approval in lupus nephritis, findings from a recent survey conducted by ...

Daily doses of obicetrapib over 52 weeks led to significant reductions in plasma p-tau217 and other Alzheimer’s disease ...

U.S. officials have rejected proposed amendments to WHO’s International Health Regulations citing concerns over vague wording ...

The FDA has approved the SetPoint System, a vagus nerve stimulator from SetPoint Medical, for the treatment of rheumatoid ...

A phase 2b study evaluating repibresib gel in nonsegmental vitiligo did not meet its primary endpoint and an ongoing ...

The level of neighborhood deprivation was associated with cognitive speed concerns for individuals on the cusp of midlife, ...

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

In this Healio Video Perspective from the American Society of Retina Specialists annual meeting, Sunir J. Garg, MD, FACS, ...

Exercise-based cardiac rehabilitation may improve symptom burden, exercise capacity and health-related quality of life for ...

AbbVie released positive topline data from its phase 3 UP-AA trial demonstrating safety and efficacy for upadacitinib for ...

V Foundation for Cancer Research has named Diana Hargreaves, PhD, a 2025 All-Star Translational Award Program grantee, ...

Patients receiving prolonged mechanical ventilation discharged from the ICU had better outcomes related to 6-month mortality ...